BIOSECURE and the CDMO reshuffle: the hiring behind supply chain moves

The BIOSECURE Act is law and companies are rethinking where their drugs are made. Why that creates demand for tech transfer, supplier quality and CMC talent.

The BIOSECURE Act was signed into US law on 18 December 2025 as part of the National Defense Authorization Act for fiscal year 2026. It restricts US government contracting with organisations that use designated foreign biotechnology companies of concern, with the list of designated companies due by 18 December 2026 and prohibitions phasing in over the following years.

The details are still moving. In August 2026 a US court enjoined the Department of Defense listing of WuXi AppTec, one of the largest contract research, development and manufacturing organisations. But the direction of travel is clear, and companies are acting now: a manufacturing partner chosen in 2026 may still be supplying a product in the 2030s.

Why this matters for hiring

Dependence on overseas partners is widespread. A Biotechnology Innovation Organization survey found that 79% of responding biopharma companies had at least one contract or product agreement with a China-based or China-owned CDMO or CMO. Moving even part of that work, combined with tariff-driven reshoring, creates projects that need specific people:

  • Tech transfer and MSAT specialists to move processes between sites and partners.
  • Supplier quality engineers and auditors to qualify new manufacturers.
  • CMC and regulatory CMC professionals to manage the filings that follow a change of site.
  • External manufacturing and supply chain managers to run a broader partner network.

Who is hiring

Demand is landing on both sides: sponsors building internal teams to manage new partners, and Western CDMOs expanding capacity to take on the work. Both are recruiting from the same small pool of people who have done a transfer before.

If you are planning a site change or a new manufacturing partner, we can build the team around it across the US, UK and Europe. This article is general information, not legal advice.

Sources: Greenberg Traurig, BIOSECURE Act update. KBI Biopharma, BIOSECURE, tariffs and the new CDMO reality. South China Morning Post, US reshoring and contract drug makers.

Have a role to fill?

Register it in five minutes. Your intake starts straight away, any time of day, and you pay nothing until your hire starts.